Africa’s leading drug manufacturer Aspen Pharmacare Holdings has reportedly agreed to acquire a unit of competitor Mereck & Co in a deal worth about $1 billion. In a statement, Aspen CEO Stephen Saad said the acquisition will aid his company’s output in Latin America and Asia, where the firm looks to strength its roots. According to reports, the agreement involves the buyout of a products unit, which uses molecules for therapeutic treatment including hormone replacement therapy and oral contraceptives. Aspen’s drugs unit is based in the Netherlands. The deal is the largest divestment made by Mereck since 2009.
Featured News
Judge Pushes for Faster Pace in NASCAR Antitrust Trial
Dec 8, 2025 by
CPI
Trump Plans Executive Order This Week to Squelch State AI Regulations
Dec 8, 2025 by
CPI
US President Raises Antitrust Worries Over Netflix–Warner Bros. Deal
Dec 8, 2025 by
CPI
Freshfields Adds Former DOJ Antitrust Leader as Partner in San Francisco
Dec 8, 2025 by
CPI
Appeals Court Lifts Injunction, Allowing Florida to Enforce Social Media Age Restriction Law
Dec 8, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Intellectual Property
Nov 19, 2025 by
CPI
Dealing in Intellectual Property: IP Justifications and Defenses in Digital Markets Cases
Nov 19, 2025 by
Jennifer Dixton
The Evolving Role of Innovation Theories of Harm in the Antitrust Analysis of Life Science Mergers
Nov 19, 2025 by
Michelle Yost Hale, Matthew D. McDonald & Merrill Stovroff
Who Can Fix It? Antitrust, IP Rights, and the Right to Repair
Nov 19, 2025 by
Rosa M. Morales
Copyright, Antitrust, and the Politics of Generative AI
Nov 19, 2025 by
Daryl Lim